These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 7379358

  • 1. 1 alpha-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function.
    Nielsen HE, Rømer FK, Melsen F, Christensen MS, Hansen HE.
    Clin Nephrol; 1980 Mar; 13(3):103-8. PubMed ID: 7379358
    [Abstract] [Full Text] [Related]

  • 2. Decreased renal function in association with administration of 1,25-dihydroxyvitamin D3 to patients with stable, advanced renal failure.
    Christiansen C, Røodbro P, Christensen MS, Naestoft J, Hartnack B, Transbøol I.
    Contrib Nephrol; 1980 Mar; 18():139-46. PubMed ID: 6243527
    [Abstract] [Full Text] [Related]

  • 3. Influence of 1 alpha-hydroxy vitamin D3 (0.25 micrograms/day) and calcium carbonate on patients with chronic renal failure at the predialytic stage.
    Okada K, Nagura Y, Takahashi S, Hatano M.
    Nihon Jinzo Gakkai Shi; 1989 Jun; 31(6):657-60. PubMed ID: 2795995
    [Abstract] [Full Text] [Related]

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 5. Effects of 24R,25-dihydroxyvitamin D3 in combination with 1 alpha-hydroxyvitamin D3 in predialysis renal insufficiency: biochemistry and histomorphometry of cancellous bone.
    Birkenhäger-Frenkel DH, Pols HA, Zeelenberg J, Eijgelsheim JJ, Schot R, Nigg AL, Weimar W, Mulder PG, Birkenhäger JC.
    J Bone Miner Res; 1995 Feb; 10(2):197-204. PubMed ID: 7754799
    [Abstract] [Full Text] [Related]

  • 6. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
    Lee SH, Huang TS, Hsieh SJ.
    Miner Electrolyte Metab; 1996 Feb; 22(4):219-23. PubMed ID: 8807625
    [Abstract] [Full Text] [Related]

  • 7. Results of long-term treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium.
    Lindholm TS, Eriksson S, Lindholm TC.
    Ital J Orthop Traumatol; 1984 Jun; 10(2):187-201. PubMed ID: 6432736
    [Abstract] [Full Text] [Related]

  • 8. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers.
    Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C.
    Nephrol Dial Transplant; 2008 Nov; 23(11):3670-6. PubMed ID: 18579534
    [Abstract] [Full Text] [Related]

  • 9. 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study.
    Berl T, Berns AS, Hufer WE, Hammill K, Alfrey AC, Arnaud CD, Schrier RW.
    Ann Intern Med; 1978 Jun; 88(6):774-80. PubMed ID: 208439
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure.
    Rix M, Eskildsen P, Olgaard K.
    Nephrol Dial Transplant; 2004 Apr; 19(4):870-6. PubMed ID: 15031343
    [Abstract] [Full Text] [Related]

  • 12. [Effect of 1,25-dihydroxycholecalciferol in renal osteopathy].
    Reutter FW, Sieber R, Olah AJ, Dambacher MA.
    Schweiz Med Wochenschr; 1979 Dec 08; 109(47):1880-3. PubMed ID: 531567
    [Abstract] [Full Text] [Related]

  • 13. 1alpha-hydroxychloecalciferol treatment of long-term hemodialyzed patients. Effects on mineral metabolism, bone mineral content and bone morphometry.
    Nielsen HE, Melsen F, Christensen MS, Hansen HE, Rodbro P, Johannsen A.
    Clin Nephrol; 1977 Oct 08; 8(4):429-34. PubMed ID: 923161
    [No Abstract] [Full Text] [Related]

  • 14. Effects of 1,25-dihydroxyvitamin-D3 on renal function, mineral balance, and growth in children with severe chronic renal failure.
    Chan JC, Kodroff MB, Landwehr DM.
    Pediatrics; 1981 Oct 08; 68(4):559-71. PubMed ID: 6895662
    [Abstract] [Full Text] [Related]

  • 15. L-alpha-hydroxycholecalciferol treatment of adults with chronic renal failure.
    Madsen S, Olgaard K.
    Acta Med Scand; 1976 Oct 08; 200(1-2):1-5. PubMed ID: 961464
    [Abstract] [Full Text] [Related]

  • 16. Evolution of renal osteodystrophy: correlation of bone histomorphometry and serum mineral and immunoreactive parathyroid hormone values before and after treatment with calcium carbonate or 25-hydroxycholecalciferol.
    Bordier PJ, Marie PJ, Arnaud CD.
    Kidney Int Suppl; 1975 Jan 08; (2):102-12. PubMed ID: 1057669
    [No Abstract] [Full Text] [Related]

  • 17. Hyperparathyroid bone disease in diabetic renal failure.
    Cundy TF, Humphreys S, Watkins PJ, Parsons V.
    Diabetes Res; 1990 Aug 08; 14(4):191-6. PubMed ID: 2132193
    [Abstract] [Full Text] [Related]

  • 18. Action of 1alpha-hydroxy vitamin D3 on calcium absorption and bone resorption in man.
    Peacock M, Gallagher JC, Nordin BE.
    Lancet; 1974 Mar 09; 1(7854):385-89. PubMed ID: 4131034
    [No Abstract] [Full Text] [Related]

  • 19. Bone aluminum content in predialysis chronic renal failure and its relation with secondary hyperparathyroidism and 1,25(OH)2D3 treatment.
    Coen G, Mazzaferro S, Costantini S, Ballanti P, Carrieri MP, Giordano R, Smacchi A, Sardella D, Bonucci E, Taggi F.
    Miner Electrolyte Metab; 1989 Mar 09; 15(5):295-302. PubMed ID: 2811788
    [Abstract] [Full Text] [Related]

  • 20. Long-term therapy of uremic osteodystrophy in adults with calcitriol.
    Moorthy AV, Harrington AR, Mazess RB, Simpson DP.
    Clin Nephrol; 1981 Aug 09; 16(2):93-100. PubMed ID: 6894893
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.